Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders
about
Genome and transcriptome of the porcine whipworm Trichuris suisOral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel diseaseThe functions of type I and type II natural killer T cells in inflammatory bowel diseasesInduction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob miceThe identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides.Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.Serum metabolome and lipidome changes in adult patients with primary dengue infection.Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trialAltered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.Roles of CD1d-restricted NKT cells in the intestine.beta-Glycosphingolipids as immune modulators.The contrasting roles of NKT cells in tumor immunity.Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent.Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.Physiological functions and clinical implications of sphingolipids in the gut.Targeting the diverse immunological functions expressed by hepatic NKT cells.Hepatoprotective effect of DT56a is associated with changes in natural killer T cells and regulatory T cells.Immune therapy for hepatocellular carcinoma.Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity.Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.Oral Co-administration of Soy-derived Extracts with Alcohol or with Sugar-sweetened Beverages Exerts Liver and Sugar Protective Effects.Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells.Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.Metabolism, physiological role, and clinical implications of sphingolipids in gastrointestinal tract.Beta-glycoglycosphingolipid-induced alterations of the STAT signaling pathways are dependent on CD1d and the lipid raft protein flotillin-2.Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.Beta-glucosylceramide ameliorates liver inflammation in murine autoimmune cholangitis.Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat.Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping.A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection.Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury.Beta-testing NKT cell self-reactivity
P2860
Q22122068-8700CBB0-FC04-4633-B4EB-273820C6CF01Q26768500-EB35DC0A-2A58-4AA7-8DC4-6289F987F57FQ26865391-58B9D5B5-73D2-4932-BE8F-8B80EC5EBDE1Q34006674-8AF0DB4D-A17E-4D54-A8C9-630B9DA74E19Q34453044-94AF5447-6D3A-48EB-9EC9-F76A913583B2Q34519826-843DD6FC-DDDB-4ECB-BFD1-5D08E484424EQ34965777-0B63639E-DDB4-4B74-8703-8370E1D9B114Q35594296-4F29A228-8C7C-4893-8397-C73BE309EF64Q35783896-48EFEFB1-8EAC-4783-84DF-8BF9C50541D4Q36095320-59CA576C-B0B1-445C-ADA5-C77E335B9840Q36809882-A931B2EA-E2C4-4169-BA27-30C5C7E3451CQ37196707-70738E8F-2999-429E-A0A1-994C7E8FC4A6Q37312825-4CD56531-C19D-45BC-A363-BDA9E93DC8A4Q37520646-5ED69D75-3AAE-4420-AB86-53F35187FADCQ37563673-7483ED81-EB65-4909-B12C-15CB4C41A8DBQ37614595-6EDA9115-1E7C-4657-A596-6BA3AD8F79C0Q37852814-8EF54576-54F6-4D3D-BDEF-CA807F93EC93Q37874633-C267EE46-7825-4B3F-93E0-9EC4A3E639E1Q38320192-55F9F2AA-945B-49D6-B3C4-AD4557771EE0Q38552117-25B235F1-CF00-4BFE-8922-4817801214CFQ38833111-5D9EE3AD-5486-4E4C-90EE-3A7C3F6F4201Q40266099-B4CEF892-A393-464C-9678-39296AB36957Q41174004-F3EB0AC9-76D6-4CA5-AA44-FD938133A741Q41706852-AB7618AA-AB42-45F9-9C9C-C9A47ABE5BD0Q42095955-0BD3EC7A-E679-4DF7-BFA4-B50768114B17Q42954809-52351702-38A8-4FCC-8130-527CE3B17866Q42971462-35CB84DE-7992-4E89-907A-3AA931E22F6AQ43143368-D7F41A8E-6972-4516-A884-FA00B7A5E220Q43759628-2FFF2095-3967-4ECC-B14A-2E276244E134Q44408019-85EBD992-7388-4A5B-A788-59CC8C58EC01Q46199134-837922DA-0A3E-4195-955D-90B65BDD770CQ46305232-A9C3BECE-65BF-44E6-B976-A8F0F17FE717Q46595862-A9579C9B-B946-4B53-B918-CA0185AA29EEQ55014958-8930A808-1537-4151-8FAC-B96370BD003AQ55313239-B6937743-7EA8-48D8-A429-CBA4B3FBE146Q56916655-ECC6A32B-CEFD-46AA-B976-E77187B3796A
P2860
Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@ast
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@en
type
label
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@ast
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@en
prefLabel
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@ast
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@en
P2093
P2860
P356
P1433
P1476
Beta-glucosylceramide: a novel ...... s of immune-mediated disorders
@en
P2093
D Friedman
L Zolotarov
M Margalit
P2860
P356
10.1136/GUT.2006.095497
P407
P577
2007-01-01T00:00:00Z